Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.

MLA

Neal, Joel W., et al. “Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.” JTO Clinical and Research Reports, vol. 5, no. 10, Mar. 2024, p. 100666. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2024.100666.

APA

Neal, J. W., Santoro, A., Gonzalez-Cao, M., Lim, F. L., Fang, B., Gentzler, R. D., Goldschmidt, J., Khrizman, P., Proto, C., Patel, S., Puri, S., Liu, S. V., Massarelli, E., Williamson, D., Schwickart, M., Scheffold, C., Andrianova, S., & Felip, E. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports, 5(10), 100666. https://doi.org/10.1016/j.jtocrr.2024.100666

Chicago

Neal, Joel W, Armando Santoro, Maria Gonzalez-Cao, Farah Louise Lim, Bruno Fang, Ryan D Gentzler, Jerome Goldschmidt, et al. 2024. “Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.” JTO Clinical and Research Reports 5 (10): 100666. doi:10.1016/j.jtocrr.2024.100666.